Kenneth B. McCredie

TL;DR: Hematologic remission of the disease was obtained in 5 patients and enlarged spleens decreased in 3 of 3 patients maintained on HuIFN-alpha, 3 X 10(6) U daily or every other day, for 6-35+ wk.

TL;DR: The beneficial association of therapy with survival was demonstrated by the significantly longer median survival of patients treated since 1981 compared with those treated earlier, even after accounting for the pretreatment prognostic factors, and by the significant improvement in survival of Patients achieving remission using the "landmark" analysis technique.

TL;DR: By providing an objective estimate of prognosis in accelerated disease, the model identifies patients in need of different therapeutic interventions before the development of blastic crisis and identified five features that have additive independent prognostic importance.

TL;DR: A multivariate analysis of prognostic factors demonstrated the cytogenetic pattern to be the most important characteristic determining remission rate and survival and important prognostic features were the morphologic presentation (MDS v acute leukemia) for probability of achieving remission, and patient age and marrow blasts percentage for survival.

TL;DR: Repeat leukapheresis of the same donor does not reduce the number of circulating colony-forming cells in the peripheral blood of man.